Historical record - last NADAC publication: 5/22/2024
Product Information
KALETRA 200-50 MG TABLET is a brand product labeled by AbbVie Inc., priced at $8.3041 per EA under NDC 00074679922. Its NADAC has been published 486 times since Nov 28, 2013.
Strength
200; 50 mg/1; mg/1
Manufacturer
AbbVie Inc.NDC
00074679922
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
5/22/2024
Active Ingredients
LOPINAVIR; RITONAVIRApproval Type
New Drug (NDA)
FDA Application
NDA021906On Market Since
6/18/2010
Pharmacological Classes
Price Statistics
The NADAC for KALETRA 200-50 MG TABLET has been published 486 times since Nov 28, 2013, and over the history we have for it it has risen 33.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.3041 per EA |
|---|---|
| All-time high | $8.3532 (Mar 10, 2021) |
| All-time low | $6.1999 (Dec 18, 2013) |
| Median price | $8.2614 |
| Average price | $7.7849 |
| Largest weekly change | +6.9% (Jan 6, 2016) |
| Weeks tracked | 486 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 47% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of KALETRA 200-50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for KALETRA 200-50 MG TABLET, manufactured by AbbVie Inc., is $8.3041 per EA (NDC 00074679922), effective May 14, 2025.
How has the price of KALETRA 200-50 MG TABLET changed over time?
Over the history we have for it, the NADAC for KALETRA 200-50 MG TABLET has risen 33.2%. It has been tracked across 486 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for KALETRA 200-50 MG TABLET?
Since Nov 28, 2013, the NADAC for KALETRA 200-50 MG TABLET has ranged from a low of $6.1999 (Dec 18, 2013) to a high of $8.3532 (Mar 10, 2021), with a median of $8.2614 per EA.
Are there cheaper alternatives to KALETRA 200-50 MG TABLET?
Yes. 2 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, LOPINAVIR-RITONAVR 200-50 MG TB, is $4.4210 per EA — about 47% below KALETRA 200-50 MG TABLET.
Who manufactures KALETRA 200-50 MG TABLET?
KALETRA 200-50 MG TABLET (NDC 00074679922) is labeled by AbbVie Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification